STAT June 29, 2024
Nicholas Florko, Lizzy Lawrence, John Wilkerson, Elaine Chen

The Food and Drug Administration’s power to make important regulatory decisions is in question after a Supreme Court decision weakening federal agencies’ ability to interpret ambiguous statutory measures. The ruling could mean headaches not just for the teams of lawyers and scientists at the FDA, but for the drug and device companies the agency is charged with regulating.

While the Supreme Court’s decision is not expected to have major implications on the FDA’s bread and butter task —...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Pharma, Pharma / Biotech, Regulations
Bringing genomics closer to patients: 3 takeaways from Henry Ford Health
Merck enters $2B licensing deal for weight loss drug
What are pharmacy benefit managers? A health economist explains how lack of competition drives up drug prices
How Medicare Negotiated Drug Prices Compare to Other Countries
The Fed's Warnings On Inflation Are Bad News For Biotech Startups

Share This Article